top of page
My Post - 2021-07-08T181150.838.png
My Post - 2021-09-08T095837.157.png

GenieBiome found 4 Bacteria gene markers for diagnosis of colorectal cancer and adenoma...



"Our proprietary microbial biomarkers are non-invasive, biologically relevant, and disease-specific..."

GenieBiome’s biomarker discovery platform utilizes in-depth metagenomic analysis of large human microbial datasets and in-house proprietary machine learning approaches to identify diagnostic microbiome signatures targeted to different human diseases. The gut microbiome is a rich source of biologically relevant biomarkers that can be transformed into precise diagnostic and prognostic tools. Clinicians can use them as non-invasive early diagnostic and monitoring tools to optimize clinical decisions and improve patient care.

Diagnostics Approach

Solution & Product


A stool microbiome precision test for early detection of colorectal adenoma and cancer.

GenieBiome (Diagnostic) has developed one of the world’s first microbiome-based diagnostic products to disrupt the diagnostic landscape of cancer diagnosis. Starting with one of the top killers globally, colorectal cancer, we have identified species-specific bacterial gene markers for the early detection of colorectal cancer and adenomas. Our bacteria markers can detect colorectal cancer early when it can be cured, and it can detect adenomas and prevent cancer development. 

Solution & Product
Sub Logo-01.png


The Features of M3CRC
WORLD’S ONLY non-invasive colorectal cancer risk prediction test that detects non-advanced adenoma

94% sensitivity for CRC is as robust as colonoscope

Sensitivity for adenoma is superior to currently available non-invasive tests

Non-invasive, just stool sample is needed

Dietary recommendations included 

Tailored for Asians

Leaflet Graphics-01.png
Using metagenomics analysis, we identified
20 gene markers that significantly differentiate
CRC-associated and control microbiomes.
gradient (1).png
Principal component analysis based on abundances of 20 gene markers separates CRC cases and control individuals significantly. 
gradient (1).png
CRC index computed using a simple unweighted linear combination of log-abundance of 20 gene markers significantly distinguished patients with CRC (red) and control individuals (green), but not patients with type 2 diabetes or IBD and control individuals from other studies, suggesting that the 20 gene markers are CRC-specific. The box depicts the IQRs between the first and third quartiles, and the line inside denotes the median.
gradient (1).png
M3CRC shows good diagnostic performance in discriminating patients with CRC and adenoma from control subjects according to receiver operating characteristic (ROC) curves analysis, with areas under ROC of 0.9763 and 0.7328 respectively.

The advantages of M3CRC


M3CRC is the world’s only non-invasive colorectal cancer risk prediction test that defects non-advanced adenoma, the sensitivity of CRC is 94% comparable to colonoscopy and the specificity is 85%, sensitivity superior to currently available non-invasive test in detecting adenomas.


*at 85% specificity
CRC: colorectal cancer
‍AA: advanced adenoma
‍nAA: non-advanced adenoma
#Sample size increased since the publication of Ref. 10. Data on file.

4. Asset 2_800x-EN.png

A persistently high score indicates a hostile microbial environment that is favorable for the development of CRC.

5. Asset 3_800x-EN.png


‍A novel tool for monitoring gut microbial health

Blue Raspberry.jpg


When Should I take the Test?

To predict the risk of having colorectal adenoma and colorectal cancer: >45 years old. The American Cancer Society (ACS) recommends that adults aged 45 years or above with an average risk of colorectal cancer undergo regular screening. In certain high-risk individuals, including those with a family history of colorectal cancer, and inherited mutations, or other known risk factors, screening is recommended to begin at an earlier age. For stool-based tests, the ACS recommends regular screening every 1-3 years. For more information, please consult your doctor.

For regular monitoring of gut microbial health: Any age M3CRC can inform you of exposure to a hostile microbial environment that can promote colorectal cancer. Anyone can take the test to stay informed about his or her colorectal cancer-related gut microbial health. Please consult your doctor if you are interested in the test.

What kind of information will be included in the report?

M3CRC measures the levels of m3 and the other 3 microbial markers plus hemoglobin in the stool. Using our propriety algorithm, we generate 3 risk indices corresponding to colorectal adenoma, colorectal cancer and colorectal adenoma recurrence. Higher risk indices reflect higher risks of having colorectal adenoma, colorectal cancer and colorectal adenoma recurrence.

bottom of page